Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares rose 4. 4% in pre-market trading after Leerink Partners assumed coverage of the biotechnology company with an Outperform rating and an $8 price target.
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, Boston, MA. Fireside discussion, September 8, 2026, 4:30p
This is the newest page. Registered accounts read further back.